Abstract
117 Background: The aim of this study is to describe initial treatment of men diagnosed with prostate cancer in the United States (US) between 2004 and 2011. Methods: Subjects with adenocarcinoma of the prostate were identified using the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program between 2004 and 2011. Subjects were staged according the American Joint Committee on Cancer (AJCC) 7th edition criteria. The National Comprehensive Cancer Network (NCCN) risk group classifications were used to stratify subjects into low risk (LR) including very low risk, intermediate risk (IR), high risk (HR) and very high (VHR) groups. Surgical intervention was grouped into no surgery, prostatectomy or other which included cyroablative therapy, hyperthermia, laser ablation, TURP, etc. Descriptive statistics and analysis were performed using Microsoft Office 2013 Excel. Results: There were 306,694 PC subjects with sufficient data to be risk categorized. Overall, 35.0% of subjects had LR, 36.1% had IR, 22.5% had HR, 1.2% had VHR, 0.6% had node positive and 4.6% had metastatic disease. Table 1 reveals the surgical and radiation treatment distribution for each risk group. Between 2004 and 2011 the use of prostatectomy, no treatment and external beam RT (EBRT) increased and the use of brachy including brachy monotherapy and brachytherapy in combination with EBRT decreased. Age is a strong influence on treatment delivered. Conclusions: This patterns of care study shows the heterogeneity of therapy for PC stratified by risk group in a contemporary series. Trends in treatment may reflect the development of new technology and findings from randomized trials. [Table: see text]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.